GB1033844A - Combinations of aluminum-chelating therapeutic adjuvants and aluminum chelates and process for making and using the same - Google Patents
Combinations of aluminum-chelating therapeutic adjuvants and aluminum chelates and process for making and using the sameInfo
- Publication number
- GB1033844A GB1033844A GB3608564A GB3608564A GB1033844A GB 1033844 A GB1033844 A GB 1033844A GB 3608564 A GB3608564 A GB 3608564A GB 3608564 A GB3608564 A GB 3608564A GB 1033844 A GB1033844 A GB 1033844A
- Authority
- GB
- United Kingdom
- Prior art keywords
- aluminium
- acid
- hydroxy
- carboxylic acid
- metal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229910052782 aluminium Inorganic materials 0.000 title abstract 9
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 title abstract 9
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 239000002671 adjuvant Substances 0.000 title 1
- 239000004411 aluminium Substances 0.000 abstract 8
- -1 alkali metal aluminate Chemical class 0.000 abstract 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 5
- 229910052784 alkaline earth metal Inorganic materials 0.000 abstract 4
- 229910052751 metal Inorganic materials 0.000 abstract 4
- 239000002184 metal Substances 0.000 abstract 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
- 239000013522 chelant Substances 0.000 abstract 3
- 239000004310 lactic acid Substances 0.000 abstract 3
- 235000014655 lactic acid Nutrition 0.000 abstract 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 abstract 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 abstract 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 abstract 2
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 abstract 2
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 2
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 abstract 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 abstract 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 2
- 239000003513 alkali Substances 0.000 abstract 2
- 150000001342 alkaline earth metals Chemical class 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 229910052797 bismuth Inorganic materials 0.000 abstract 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- XFTRTWQBIOMVPK-UHFFFAOYSA-N citramalic acid Chemical compound OC(=O)C(O)(C)CC(O)=O XFTRTWQBIOMVPK-UHFFFAOYSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000001704 evaporation Methods 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 231100000252 nontoxic Toxicity 0.000 abstract 2
- 230000003000 nontoxic effect Effects 0.000 abstract 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 abstract 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 abstract 2
- 229910052708 sodium Inorganic materials 0.000 abstract 2
- 239000011734 sodium Substances 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 abstract 1
- LKPINBXAWIMZCG-UHFFFAOYSA-N 2-(2,2-diphenylacetyl)oxyethyl-diethylazanium;chloride Chemical compound Cl.C=1C=CC=CC=1C(C(=O)OCCN(CC)CC)C1=CC=CC=C1 LKPINBXAWIMZCG-UHFFFAOYSA-N 0.000 abstract 1
- CMCCHHWTTBEZNM-UHFFFAOYSA-N 2-bromo-N-carbamoyl-3-methylbutanamide Chemical compound CC(C)C(Br)C(=O)NC(N)=O CMCCHHWTTBEZNM-UHFFFAOYSA-N 0.000 abstract 1
- NBUHTTJGQKIBMR-UHFFFAOYSA-N 4,6-dimethylpyrimidin-5-amine Chemical compound CC1=NC=NC(C)=C1N NBUHTTJGQKIBMR-UHFFFAOYSA-N 0.000 abstract 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 abstract 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 abstract 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 abstract 1
- BFSMWENDZZIWPW-UHFFFAOYSA-N Isopropamide iodide Chemical compound [I-].C=1C=CC=CC=1C(C(N)=O)(CC[N+](C)(C(C)C)C(C)C)C1=CC=CC=C1 BFSMWENDZZIWPW-UHFFFAOYSA-N 0.000 abstract 1
- 229930194542 Keto Natural products 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 abstract 1
- 239000008156 Ringer's lactate solution Substances 0.000 abstract 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 abstract 1
- JPKKQJKQTPNWTR-KQAYXBCTSA-N [(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2r)-3-hydroxy-2-phenylpropanoate;sulfuric acid;hydrate Chemical compound O.OS(O)(=O)=O.C1([C@H](CO)C(=O)OC2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1.C1([C@H](CO)C(=O)OC2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 JPKKQJKQTPNWTR-KQAYXBCTSA-N 0.000 abstract 1
- 229960001413 acetanilide Drugs 0.000 abstract 1
- 229960001138 acetylsalicylic acid Drugs 0.000 abstract 1
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- 150000001399 aluminium compounds Chemical class 0.000 abstract 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 abstract 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 abstract 1
- ANBBXQWFNXMHLD-UHFFFAOYSA-N aluminum;sodium;oxygen(2-) Chemical compound [O-2].[O-2].[Na+].[Al+3] ANBBXQWFNXMHLD-UHFFFAOYSA-N 0.000 abstract 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 abstract 1
- 125000003368 amide group Chemical group 0.000 abstract 1
- 229960004050 aminobenzoic acid Drugs 0.000 abstract 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 abstract 1
- 229960003556 aminophylline Drugs 0.000 abstract 1
- 229960004909 aminosalicylic acid Drugs 0.000 abstract 1
- 229940035676 analgesics Drugs 0.000 abstract 1
- 229940069428 antacid Drugs 0.000 abstract 1
- 239000003159 antacid agent Substances 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 230000001458 anti-acid effect Effects 0.000 abstract 1
- 230000001754 anti-pyretic effect Effects 0.000 abstract 1
- 230000003356 anti-rheumatic effect Effects 0.000 abstract 1
- 230000002921 anti-spasmodic effect Effects 0.000 abstract 1
- 230000002365 anti-tubercular Effects 0.000 abstract 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 abstract 1
- 239000002221 antipyretic Substances 0.000 abstract 1
- 229940125716 antipyretic agent Drugs 0.000 abstract 1
- 239000003435 antirheumatic agent Substances 0.000 abstract 1
- 229940124575 antispasmodic agent Drugs 0.000 abstract 1
- 229960002319 barbital Drugs 0.000 abstract 1
- 229960001948 caffeine Drugs 0.000 abstract 1
- RCQXSQPPHJPGOF-UHFFFAOYSA-N caffeine citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C RCQXSQPPHJPGOF-UHFFFAOYSA-N 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 abstract 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
- 125000002843 carboxylic acid group Chemical group 0.000 abstract 1
- 230000009920 chelation Effects 0.000 abstract 1
- 239000000812 cholinergic antagonist Substances 0.000 abstract 1
- 239000008367 deionised water Substances 0.000 abstract 1
- 229910021641 deionized water Inorganic materials 0.000 abstract 1
- QSDQMOYYLXMEPS-UHFFFAOYSA-N dialuminium Chemical compound [Al]#[Al] QSDQMOYYLXMEPS-UHFFFAOYSA-N 0.000 abstract 1
- BKMLGCPWXVBXHY-UHFFFAOYSA-N diethyl-(2-hydroxyethyl)-methylazanium Chemical compound CC[N+](C)(CC)CCO BKMLGCPWXVBXHY-UHFFFAOYSA-N 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 229940030606 diuretics Drugs 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000004222 ferrous gluconate Substances 0.000 abstract 1
- 235000013924 ferrous gluconate Nutrition 0.000 abstract 1
- 229960001645 ferrous gluconate Drugs 0.000 abstract 1
- 210000004051 gastric juice Anatomy 0.000 abstract 1
- 239000005554 hypnotics and sedatives Substances 0.000 abstract 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 abstract 1
- 239000001095 magnesium carbonate Substances 0.000 abstract 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 abstract 1
- 229960002510 mandelic acid Drugs 0.000 abstract 1
- 229940051129 meperidine hydrochloride Drugs 0.000 abstract 1
- 229960003512 nicotinic acid Drugs 0.000 abstract 1
- 235000001968 nicotinic acid Nutrition 0.000 abstract 1
- 239000011664 nicotinic acid Substances 0.000 abstract 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229960003893 phenacetin Drugs 0.000 abstract 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 abstract 1
- 229960002695 phenobarbital Drugs 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 abstract 1
- 229960000581 salicylamide Drugs 0.000 abstract 1
- 150000003873 salicylate salts Chemical class 0.000 abstract 1
- 229960004889 salicylic acid Drugs 0.000 abstract 1
- 229960004499 scopolamine hydrobromide Drugs 0.000 abstract 1
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 abstract 1
- CXYRUNPLKGGUJF-RAFJPFSSSA-M scopolamine methobromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 CXYRUNPLKGGUJF-RAFJPFSSSA-M 0.000 abstract 1
- 229910001388 sodium aluminate Inorganic materials 0.000 abstract 1
- JZLOKWGVGHYBKD-UHFFFAOYSA-M sodium;2-acetyloxybenzoate Chemical compound [Na+].CC(=O)OC1=CC=CC=C1C([O-])=O JZLOKWGVGHYBKD-UHFFFAOYSA-M 0.000 abstract 1
- KMPHTYSTEHXSTL-UHFFFAOYSA-M sodium;2-hydroxypropanoate;2-hydroxypropanoic acid Chemical compound [Na+].CC(O)C(O)=O.CC(O)C([O-])=O KMPHTYSTEHXSTL-UHFFFAOYSA-M 0.000 abstract 1
- 238000010998 test method Methods 0.000 abstract 1
- VXYADVIJALMOEQ-UHFFFAOYSA-K tris(lactato)aluminium Chemical compound CC(O)C(=O)O[Al](OC(=O)C(C)O)OC(=O)C(C)O VXYADVIJALMOEQ-UHFFFAOYSA-K 0.000 abstract 1
- 239000000083 urinary anti-infective agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/06—Aluminium compounds
- C07F5/069—Aluminium compounds without C-aluminium linkages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Aluminium chelates, having the empirical formula <FORM:1033844/C2/1> wherein m, n, x, y are numbers whose sum balances the positive valences of the aluminium and metal M, which represents a non-toxic alkali or alkaline-earth metal or bismuth, m + y is the total number of gram atoms of the metal M, m + n is the total number of gram molecular weights of the a - or b -hydroxy alphatic carboxylic acid, R being the residue thereof, and m is from 1 to 3, n from 0 to 3, and y from 0 to 1.5, are prepared by reacting an appropriate aluminium compound, e.g. an alkali metal aluminate or aluminium hydroxide or Al2(OH)xCly, where x + y = 6 and x and y are at least 1, with a suitable a - or b -aliphatic hydroxy carboxylic acid, e.g. lactic, glycolic, gluconic, trihydroxy glutaric, citryl trigluconic, tartaric, malic, citric, citramalic or tetrahydroxy adipic acid. In typical examples: a sodium aluminium lactate chelate (weight ratio lactic acid: aluminium 2.5: 1) was prepared by reacting sodium aluminate with a lactic acid-sodium lactate solution in water; a sodium aluminium chlorhydroxy lactate was prepared by mixing Al2(OH)5Cl with lactic acid in water, adding NaOH to adjust pH to 6.2, and evaporating water therefrom; magnesium aluminium hydroxy lactate was prepared by mixing aluminium hydroxide gel with lactic acid in deionized water, adding magnesium carbonate to the heated aqueous solution, and evaporating water to leave a dry solid.ALSO:Therapeutic antacid compositions consist of an aluminium-chelating therapeutic agent having at least one radical (e.g. a hydroxyl, keto carboxyl, ester, amino or amido group) available for chelation with aluminium and an aluminium chelate of an a - or b -hydroxy aliphatic carboxylic acid, having a pH in aqueous solution of about 3 to about 9, and having the empirical formula <FORM:1033844/A5-A6/1> wherein m, n, x, and y are numbers whose sum balances the positive valences of the metal M and aluminium, m + n equals the total number of gram molecular weights of the hydroxy aliphatic carboxylic acid, m + y equals the total number of gram atoms of the metal, m is from 1 to 3, n is from 0 to 3, y is from 0 to 1.5, M is a non-toxic alkali or alkaline earth metal or bismuth, and R represents the residue of the hydroxy aliphatic carboxylic acid, which has at least one hydroxy group and at least one carboxylic acid group for each one to six carbon atoms, the aluminium chelate being present in an amount to maintain the pH of artificial gastric juice (as determined by the Holbert, Noble, and Grote test method) from about 3 to about 9 for at least one hour. The hydroxy aliphatic carboxylic acid residue may be derived from lactic, glycolic, gluconic, trihydroxy glutaric, citryl trigluconic, tartaric, malic, citric, citramalic or tetrahydroxy adipic acid. Preferred aluminium chelating therapeutic agents are anticholinergics e.g. diethyl (2-hydroxyethyl) methyl ammonium a -phenyl cyclohexaneglycolate bromide, scopolamine methyl bromide, (3-carbamoyl-3, 3-diphenylpropyl) diisopropylmethyl ammonium iodide; antispasmodics e.g. atropine sulphate, 2-diethylaminoethyl diphenylacetate hydrochloride, meperidine hydrochloride; analgesics and antipyretics e.g. aspirin, acetophenetidin, optionally with citrated caffeine, sodium acetylsalicylate, salicylic acid, salicylamide, acetanilide and 41-hydroxyacetanilide; sedatives and hypnotics e.g. phenobarbital, barbital, 2-monobromoisovalerylurea, scopolamine hydrobromide; antitubercular preparations e.g. p-amino-salicylic acid, 2-ethylthioisomicotinamide; diuretics e.g. aminophylline; antirheumatics e.g. p-amino benzoic acid together with salicylates; antianaemia agents e.g. ferrous gluconate; anti-hypercholesterimia agents e.g. nicotinic acid; urinary antiseptics e.g. mandelic acid. The compositions may be orally administered in standard solid or liquid dosage unit forms with conventional excipients.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30961263A | 1963-09-18 | 1963-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1033844A true GB1033844A (en) | 1966-06-22 |
Family
ID=23198926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB3608564A Expired GB1033844A (en) | 1963-09-18 | 1964-09-03 | Combinations of aluminum-chelating therapeutic adjuvants and aluminum chelates and process for making and using the same |
Country Status (3)
| Country | Link |
|---|---|
| DE (1) | DE1467751A1 (en) |
| FR (2) | FR4254M (en) |
| GB (1) | GB1033844A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9731999B2 (en) | 2011-09-23 | 2017-08-15 | Iqbal Gill | Chemical admixtures for hydraulic cements |
-
1964
- 1964-09-03 DE DE19641467751 patent/DE1467751A1/en active Pending
- 1964-09-03 GB GB3608564A patent/GB1033844A/en not_active Expired
- 1964-09-17 FR FR988366A patent/FR4254M/fr not_active Expired
- 1964-10-13 FR FR1601724D patent/FR1601724A/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9731999B2 (en) | 2011-09-23 | 2017-08-15 | Iqbal Gill | Chemical admixtures for hydraulic cements |
Also Published As
| Publication number | Publication date |
|---|---|
| FR4254M (en) | 1966-07-04 |
| DE1467751A1 (en) | 1968-11-28 |
| FR1601724A (en) | 1970-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3553316A (en) | Antiperspirant compositions containing aluminum chelates of hydroxy carboxylic acids | |
| US3991176A (en) | Aluminum-zirconium anti-perspirant systems with hydroxy carboxylic compounds | |
| Shinobu et al. | Sodium N‐methyl‐D‐glucamine dithiocarbamate and cadmium intoxication | |
| SG114293G (en) | Pharmaceutical compositions | |
| US4078058A (en) | Cerium sulfadiazine for treating burns | |
| GB1066192A (en) | Improvements in or relating to silicate grout | |
| GB1033844A (en) | Combinations of aluminum-chelating therapeutic adjuvants and aluminum chelates and process for making and using the same | |
| GB1501096A (en) | Methods and pharmaceutical preparation for the treatment of hypercholesterolaemia | |
| GB1256968A (en) | ||
| Davies et al. | 65. The extent of dissociation of salts in water. Part XII. Calcium salts of some amino-acids and dipeptides | |
| GB1338071A (en) | Pharmaceutical iron preparations | |
| US3506761A (en) | Combinations of aluminum-coordinating therapeutic adjuvants and aluminum chelates and process for making and using the same | |
| US2907781A (en) | Monohydroxy magnesium aluminum salt of an amino aliphatic acid and method of preparing same | |
| US2407412A (en) | Therapeutic solutions | |
| US3335055A (en) | More stable and more soluble tetracycline compositions suitable for parenteral use and method of preparing same | |
| US3499963A (en) | Codried aluminum hydroxide-aluminum chelate antacid | |
| US5236700A (en) | Gastroprotectant compositions and use thereof | |
| US3734940A (en) | Chelates of hydroxy carboxylic acids and methods for preparing the same | |
| US3322767A (en) | Tham salts | |
| ES427653A1 (en) | 3-Hydroxyacyl aminomethyl-5-acylamino-2,4,6-triiodobenzoic acid salts as x-ray contrast agents | |
| GB1241201A (en) | Improvements in or relating to effervescent pharmaceutical compositions | |
| GB1272416A (en) | Tetracycline derivatives and a process for the preparation thereof | |
| IE38383B1 (en) | Doxycline parenteral composition | |
| US3355488A (en) | Calcium chloride salt of penicillamine | |
| ES393894A1 (en) | Piperidinemethyl ethers |